Special Analysis: Addressing Key Concerns Around the FDA’s Final LDTs Rule
Experts answer key questions related to laboratory-developed test regulation during G2 Intelligence webinar.
Practical, “What-to-Do” and “How-to-Do-It” Help to Comply with the Latest State & Federal Laws, Rules & Regulations that Affect Your Diagnostic Lab or Pathology Practice
Experts answer key questions related to laboratory-developed test regulation during G2 Intelligence webinar.
Follow the steps in this form to help you develop and implement an effective healthcare equity plan for your lab.
Recent case shows that fraud and kickback schemes involving CGx testing continue to be on the federal enforcement radar.
As of January 1, 2023, your lab may need to develop and implement a full-blown health equity plan to maintain its Joint Commission accreditation.
Completing the Advance Beneficiary Notice of Noncoverage form can be extremely complex; this guide helps simplify the process.
In this Labs in Court monthly roundup, the Texas-based pathology lab was accused of falsely billing Medicare for unnecessary tests on biopsy specimens.
How much, if any, should a whistleblower get of what the government recovers in criminal or related legal actions resulting from a qui tam suit?
New CMS guidance includes information on how labs can avoid Medicare claims denials and documentation violations related to standing orders.
Most healthcare-related enforcement actions from July and August involved urine drug tests and genetic testing.
Here’s the Advance Beneficiary Notice of Non-Coverage that you should present to patients who speak Spanish, starting August 31, 2022.
Here’s the Advance Beneficiary Notice of Non-Coverage that you should present to patients, starting August 31, 2022.